Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mpox vaccine immune response under the microscope in DRC

NCT ID NCT07499739

Knowledge-focused Sponsor: Institute of Tropical Medicine, Belgium Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 300 adults in the Democratic Republic of the Congo who received either the MVA-BN or LC16m8 mpox vaccine as part of a national campaign. Researchers collect blood samples at several time points to measure how well the vaccines trigger and maintain antibodies against the mpox virus. The goal is to understand the strength and duration of the immune response, which can help improve future vaccination efforts.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MVA-BN or LC16m8 mpox vaccine
What this could lead to
If successful, this study will clarify how well these vaccines trigger and maintain immunity against mpox, guiding future vaccination strategies.
What could go wrong
This is an observational study, not a treatment trial. Results may not apply to other populations, and immune response does not guarantee protection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Any person aged 18 years old or over at the time of giving informed consent, of any gender * Participant received the MVA-BN or LC16m8 mpox vaccine as part of the national vaccination campaign * Participant has the capacity and willingness to give informed written consent * Participant agrees to adhere to the study's follow-up schedule

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mpox are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

monkeypox prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mpox

Contacts and locations

Locations

  • Centre Convivial Kasa-Vubu

    Kinshasa, Democratic Republic of the Congo

  • Kinoise

    Kinshasa, Democratic Republic of the Congo

  • Kokolo

    Kinshasa, Democratic Republic of the Congo

More trials for these conditions

Other studies related to the condition(s) this trial covers.